ATE266044T1 - Oral wirksame peptide, die zellschädigung und zelltod verhindern - Google Patents

Oral wirksame peptide, die zellschädigung und zelltod verhindern

Info

Publication number
ATE266044T1
ATE266044T1 AT00957607T AT00957607T ATE266044T1 AT E266044 T1 ATE266044 T1 AT E266044T1 AT 00957607 T AT00957607 T AT 00957607T AT 00957607 T AT00957607 T AT 00957607T AT E266044 T1 ATE266044 T1 AT E266044T1
Authority
AT
Austria
Prior art keywords
active core
core site
cell death
methods
reducing
Prior art date
Application number
AT00957607T
Other languages
English (en)
Inventor
Douglas E Brenneman
Illana Gozes
Catherine Y Spong
Albert Pinhasov
Eliezer Giladi
Original Assignee
Univ Ramot
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot, Us Health filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE266044T1 publication Critical patent/ATE266044T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT00957607T 1999-08-18 2000-08-17 Oral wirksame peptide, die zellschädigung und zelltod verhindern ATE266044T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14995699P 1999-08-18 1999-08-18
PCT/US2000/022861 WO2001012654A2 (en) 1999-08-18 2000-08-17 Orally active peptides that prevent cell damage and death

Publications (1)

Publication Number Publication Date
ATE266044T1 true ATE266044T1 (de) 2004-05-15

Family

ID=22532517

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957607T ATE266044T1 (de) 1999-08-18 2000-08-17 Oral wirksame peptide, die zellschädigung und zelltod verhindern

Country Status (7)

Country Link
EP (1) EP1206489B1 (de)
AT (1) ATE266044T1 (de)
AU (1) AU761597B2 (de)
CA (1) CA2381981A1 (de)
DE (1) DE60010478T2 (de)
ES (1) ES2220522T3 (de)
WO (1) WO2001012654A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384908B1 (en) 1999-08-18 2008-06-10 National Institute Of Health Orally active peptides that prevent cell damage and death
US7427598B2 (en) 2000-05-31 2008-09-23 The United States Of Americas As Represented By The Secretary Of The Department Of Health And Human Services Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
US20040235747A1 (en) * 2003-01-02 2004-11-25 Ramot At Tel-Aviv University Ltd. Methods of treating and/or preventing autoimmune diseases
US7960334B2 (en) 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia
JP4878551B2 (ja) 2004-04-08 2012-02-15 貞和 相磯 運動ニューロン疾患治療薬
JP5174653B2 (ja) * 2005-03-23 2013-04-03 ラモト アト テルーアビブ ユニバーシティー リミテッド 末梢神経毒症状を処置するためのａｄｎｆポリペプチドの使用
WO2007096859A2 (en) * 2006-02-24 2007-08-30 Ramot At Tel-Aviv University Ltd. Protection of the retina against laser injury by adnf peptides such as nap and sal
WO2008084483A1 (en) 2007-01-11 2008-07-17 Ramot At Tel Aviv University Ltd. Novel therapeutics based on tau/microtubule dynamics
CN101848934A (zh) * 2007-08-24 2010-09-29 以色列特拉维夫大学拉莫特技术转移公司 使用nap样和sal样肽模拟物的神经保护
EP2467397A1 (de) 2009-08-17 2012-06-27 Ramot at Tel-Aviv University Ltd. Nap-alpha-aminoisobuttersäureanalogon mit nervenschützender wirkung
US20130053320A1 (en) 2010-02-12 2013-02-28 Ramot At Tel-Aviv University, Ltd. Treatment of anemia by adnp and adnf polypeptides
WO2012015910A2 (en) 2010-07-28 2012-02-02 Allon Therapeutics Inc. Use of adnf polypeptides for treating neurodegenerative diseases
US10118943B2 (en) 2012-05-16 2018-11-06 Ramot At Tel-Aviv University Ltd. Compounds and methods for inhibiting cell death
EP3024949B1 (de) 2013-07-24 2019-03-06 The Chinese University Of Hong Kong B3gnt5 zur verwendung als biomarker für frühgeburt
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
CN113614535B (zh) 2018-10-31 2024-08-16 亚利桑那大学评议会 用于辐射诱导的肺损伤的生物标志物和使用方法
WO2022105835A1 (en) 2020-11-19 2022-05-27 The Chinese University Of Hong Kong Assessing risk for colorectal adenoma recurrence by noninvasive means
CA3213068A1 (en) 2021-03-25 2022-09-29 Ramot At Tel-Aviv University Ltd. Compositions and articles comprising an adnf polypeptide

Also Published As

Publication number Publication date
CA2381981A1 (en) 2001-02-22
EP1206489B1 (de) 2004-05-06
WO2001012654A3 (en) 2002-01-24
DE60010478D1 (de) 2004-06-09
AU6920100A (en) 2001-03-13
AU761597B2 (en) 2003-06-05
DE60010478T2 (de) 2005-06-09
WO2001012654A2 (en) 2001-02-22
ES2220522T3 (es) 2004-12-16
EP1206489A2 (de) 2002-05-22

Similar Documents

Publication Publication Date Title
DE60010478D1 (de) Oral wirksame peptide, die zellschädigung und zelltod verhindern
ITFI930247A1 (it) Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche.
BR0116587A (pt) Uso de uma eritropoietina, composição farmacêutica, métodos para proteger, manter ou realçar a viabilidade de uma célula, tecido ou órgão isolado de um corpo mamìfero, para facilitar a trancitose de uma molécula através de uma barreira endotelial celular em um mamìfero, composição para transportar uma molécula via trancitose através de uma barreira endotelial celular, e, composição
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
WO2002048183A3 (en) Compositions of peptide crystals
NZ505073A (en) Pharmaceutical compositions comprising micelles comprising lipophilic glucocorticosteroid and only one surfactant, useful for treating allergic, inflammatory and intestinal diseases
HUP0100669A3 (en) Peptide derivatives as serine protease inhibitors, their use and pharmaceutical compositions comprising thereof
ATE215081T1 (de) Gonadotropin releasing hormon- antagonisten
SI0991407T2 (en) Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations
TR199501669A1 (tr) Peptid ve proteinlerin aerosol formülasyonlari.
NO20001567D0 (no) Bioadhesive sammensetninger og fremgangsmåter for topisk administrering av aktive midler
WO2000053217A3 (en) Prevention of fetal alcohol syndrome and neuronal cell death with adnf polypeptides
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
ATE329608T1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
NO970282L (no) Adénovirus omfattende et gen som koder for glutationperoksydase
BR9811094A (pt) Agente terapêutico para tumores linfáticos
CA2338794A1 (en) New oral formulation for 5-ht4 agonists or antagonists
DK1280558T3 (da) Halvfast indgivelsesvehikel og farmaceutiske sammensætninger
ATE248832T1 (de) Antagonisten des gonadotropin freisetzenden hormons
WO2006023665A3 (en) Il-1 antagonist formulations
PT1154786E (pt) Metodos e composicoes para alterar a secrecao de muco
DE60135261D1 (de) Arzneimittel, welches ein Peptid kleiner oder mittlerer Grösse enthält
IL153540A0 (en) THE USE OF 7beta-HYDROXY-STEROID DERIVATIVES FOR THE MANUFACTURE OF PHARMACEUTICAL COMPOSITIONS
ATE342276T1 (de) Nährstoffe aus sojabohnenprotein
IT1256623B (it) Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties